BioXcel Therapeutics (BTAI) Return on Assets (2022 - 2025)
Historic Return on Assets for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to 1.88%.
- BioXcel Therapeutics' Return on Assets fell 3400.0% to 1.88% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.88%, marking a year-over-year decrease of 3400.0%. This contributed to the annual value of 1.42% for FY2024, which is 1400.0% down from last year.
- Per BioXcel Therapeutics' latest filing, its Return on Assets stood at 1.88% for Q3 2025, which was down 3400.0% from 2.06% recorded in Q2 2025.
- In the past 5 years, BioXcel Therapeutics' Return on Assets registered a high of 0.73% during Q4 2022, and its lowest value of 2.06% during Q4 2023.
- For the 4-year period, BioXcel Therapeutics' Return on Assets averaged around 1.62%, with its median value being 1.75% (2023).
- Per our database at Business Quant, BioXcel Therapeutics' Return on Assets crashed by -13300bps in 2023 and then surged by 2300bps in 2024.
- Quarter analysis of 4 years shows BioXcel Therapeutics' Return on Assets stood at 0.73% in 2022, then plummeted by -181bps to 2.06% in 2023, then grew by 11bps to 1.83% in 2024, then decreased by -3bps to 1.88% in 2025.
- Its Return on Assets stands at 1.88% for Q3 2025, versus 2.06% for Q2 2025 and 1.74% for Q1 2025.